ALLMedicine™ Acute Myeloid Leukemia Center

Dec 4th, 2021 - Mutations in isocitrate dehydrogenase 2 (IDH2) have been noted to impact cellular differentiation in addition to DNA and histone methylation. However, little is known about the impact of IDH2 mutations on intracellular signaling. Using an isogenic...

Dec 3rd, 2021 - Phase I Dose Escalation: Primary objective is to determine the MTD and the recommended dose for Phase I Extension. Secondary objective is to investigate the safety, pharmacokinetics and efficacy of BI 836858 in combination with decitabine Phase I ...

Dec 3rd, 2021 - This is first-in-human (FIH) Phase 1, open-label, multicenter, dose escalation study with dose expansion to evaluate the safety, tolerability, and preliminary antitumor activity of JNJ-67571244 in adult participants with relapsed or refractory acu...

Dec 3rd, 2021 - Epigenetic programs are dysregulated in acute myeloid leukemia (AML) and help enforce an oncogenic state of differentiation arrest. To identify key epigenetic regulators of AML cell fate, we performed a differentiation-focused CRISPR screen in AML...

Dec 3rd, 2021 - Acute myeloid leukemia (AML) is one of the most aggressive blood cancers, with a very low survival rate and few options for participants who are unable to undergo intensive chemotherapy, the current standard of care. This study is to evaluate how ...

Jan 7th, 2021 - The NCCN Guidelines for Acute Myeloid Leukemia (AML) provide recommendations for the diagnosis and treatment of adults with AML based on clinical trials that have led to significant improvements in treatment, or have yielded new information regard...

Sep 24th, 2020 - The role of hematopoietic cell transplantation (HCT) in the management of newly diagnosed adult acute myeloid leukemia (AML) is reviewed and critically evaluated in this evidence-based review. An AML expert panel, consisting of both transplant and...

Oct 7th, 2017 - Myeloproliferative neoplasms (MPNs) are a group of heterogeneous disorders of the hematopoietic system that include myelofibrosis (MF), polycythemia vera (PV), and essential thrombocythemia (ET). PV and ET are characterized by significant thromboh...

Jul 9th, 2017 - Acute myeloid leukemia (AML) is the most common form of acute leukemia among adults and accounts for the largest number of annual deaths due to leukemias in the United States. This portion of the NCCN Guidelines for AML focuses on management and p...

Sep 14th, 2013 - These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Acute Myeloid Leukemia and discuss the clinical evidence that support the recommendations. The updates described in this article focus on the acute promyelocyt...

Dec 3rd, 2021 - Phase I Dose Escalation: Primary objective is to determine the MTD and the recommended dose for Phase I Extension. Secondary objective is to investigate the safety, pharmacokinetics and efficacy of BI 836858 in combination with decitabine Phase I ...

Dec 3rd, 2021 - This is first-in-human (FIH) Phase 1, open-label, multicenter, dose escalation study with dose expansion to evaluate the safety, tolerability, and preliminary antitumor activity of JNJ-67571244 in adult participants with relapsed or refractory acu...

Dec 3rd, 2021 - Patients will receive a single dose of CLN-049 and will be followed for safety for 28 days. CLN-049 will be administered IV.

Dec 3rd, 2021 - Acute myeloid leukemia (AML) is one of the most aggressive blood cancers, with a very low survival rate and few options for participants who are unable to undergo intensive chemotherapy, the current standard of care. This study is to evaluate how ...

Dec 2nd, 2021 - OBJECTIVES: Primary Determine whether the incidence of neutrophil engraftment is acceptable in high-risk patients with Fanconi's anemia treated with busulfan, cyclophosphamide, fludarabine, and antithymocyte globulin followed by allogeneic hematop...

Dec 1st, 2021 - Key clinical point: Alvocidib followed by cytarabine and mitoxantrone (ACM) was clinically active and well tolerated in patients with myeloid cell leukemia-1 (MCL-1)-dependent relapsed/refractory (R/R) acute myeloid leukemia (AML). Major finding:.

Dec 1st, 2021 - Key clinical point: Antimicrobial prophylaxis significantly reduced rates of bloodstream infection (BSI), invasive fungal infection (IFI), and febrile neutropenia (FN) in pediatric patients with acute myeloid leukemia (AML) receiving chemotherapy.

Dec 1st, 2021 - Key clinical point: Optimization of a traditional induction regimen with idarubicin and cytarabine (IA) with additional homoharringtonine according to day 5 peripheral blast clearance rate (D5-PBCR) ³99. 55% (D5-PBCR −) is feasible in patients with.

Dec 1st, 2021 - Key clinical point: Outpatient vs. inpatient neutropenia management after chemotherapy was not associated with an increased bacteremia incidence, treatment delays, or worse health-related quality of life (HRQoL) in pediatric patients with acute my.

Nov 24th, 2021 - Note that some links may require registration or subscription. Our Daily COVID-19 Update will not appear this Thursday or Friday in observance of the Thanksgiving holiday. Look for its return on Monday, November 29. As COVID cases continue to surg...